February 15, 2019 10:09 AM ESTUpdated 10:46 AM
News Briefing

GW Phar­ma cannabi­noid to be test­ed for Alzheimer's ag­i­ta­tion; Acor­da rev­enue plum­mets as gener­ics evis­cer­ate its fran­chise

John Carroll

Editor & Founder

→ Alzheimer’s Re­search UK is fund­ing a study at King’s Col­lege us­ing GW Phar­ma’s re­cent­ly ap­proved cannabi­noid drug Sativex in de­men­tia. The study will …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times